Oxeltis

French chemistry company at Montpellier, founded in 2010 out of the antiviral chemistry group of Idenix, which provides medicinal and process chemistry to drug developers. Designs and synthesises small molecules and nucleosides, carries out hit to lead and lead optimisation, prepares reference compounds and metabolites and scales up routes for preclinical and clinical supply for pharmaceutical and biotechnology customers.